Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2007

View Archived Issues

New pharmacokinetic data on iloperidone available

Respiratory tract-delivered vaccine confers protection against Ebola virus infection in monkeys

Takeda terminates development of fixed dose Actos + TAK-536 product

AtheroGenics to focus on diabetes for AGI-1067

FDA outlines data requirements for Provenge BLA approval

Treatment completed in prophylactic phase III trial of C1-INH for HAE

Venticute awarded fast track designation

Positive topline phase Ib findings for bavituximab in advanced cancers

Amgen to acquire Ilypsa

BNC-105 shows preclinical efficacy in prostate tumors

MF-101 reduces frequency and severity of postmenopausal hot flashes

Coronado licenses rights from Burnham to develop and commercialize Apogossypol

NIAID grant supports work on fungal antigens in chronic sinusitis

R&D highlights from BIO 2007 in Boston: Zealand Pharma

R&D highlights from BIO 2007 in Boston: BioInvent International

New vascular-targeting agent moves forward to phase II trials based on positive phase I findings

Encouraging findings emerge from first-in-man trial of peptibody AMG-386

First-in-human study of a potent pan-HER tyrosine kinase inhibitor from Pfizer

Positive results for DNA vaccine adjuvant Vaxfectin in nonhuman primates

Phase I study suggests promise for orally active VEGFR/FGFR tyrosine kinase inhibitor

CX-3543, Cylene's lead rDNA biogenesis inhibitor, discussed at ASCO

Audit to be performed on phase III trial results of PreHistin

BAY-73-4506, a multikinase inhibitor, active and well tolerated in advanced cancer

Valeant's retigabine moves towards phase II study in PHN

Recent sanofi-aventis and Kumamoto University patents impart new agents for autoimmune diseases

Priority review for Abilify in pediatric schizophrenia

Biovest to seek conditional approval of BiovaxID

Novel diagnostic agents reported in recent GE Healthcare patent

Divigel approved to treat menopausal hot flashes

Recent Helperby and 3M patents disclose new antiinfective agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...